A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520997-21-00

Enrollment

Registered

2026-04-30

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic arthritis

Brief summary

Number of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 16

Detailed description

Number of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 16, Number of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) at Week 16, Mean Change from Baseline in the Health Assessment of Questionnaire Disability Index (HAQ-DI) at Week 16, Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Intervention Due to an AE

Interventions

DRUGtulisokibart

DRUGPlacebo to MK-7240

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 16	—

Secondary

Measure	Time frame
Number of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 16, Number of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) at Week 16, Mean Change from Baseline in the Health Assessment of Questionnaire Disability Index (HAQ-DI) at Week 16, Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Intervention Due to an AE	—

Measure

Time frame

—

Outcome results

None listed

Source: EU CTIS · Data processed: May 1, 2026